ACLA Sues FDA Over Regulation of Laboratory-Developed Tests—in Texas
The choice of venue was likely inspired by the longstanding anti-regulatory stance of the state's federal judges.
The choice of venue was likely inspired by the longstanding anti-regulatory stance of the state's federal judges.
A recent report offers new insight into bankruptcy trends within the sector starting before the COVID-19 pandemic.
A written policy helps establish your right to do excluded persons checks and take appropriate actions if they come back positive.
In recent key cases, the national drug retailer must stand trial for failing to protect customers from faulty Theranos products.
The new codes have garnered attention as a future mechanism for additional reimbursement and thus deserve further discussion.
Hiring, retaining, or simply doing business with the wrong people may expose your lab to significant financial penalties.
A recent False Claims Act settlement from Kentucky represents an unusual variation on a common theme.
The end of the COVID-19 public health emergency on May 11 also brings certain flexibilities for labs and other providers to an end.
In this OIG roundup, we cover the agency’s plans to modernize and improve the useability of its Compliance Program Guidance, which was first published in 1998.
A proposed move to make noncompete agreements illegal could impact retention of some laboratory employees.
To avoid claims denials and improper billings, ensure billing and coding staff is aware of, and has adjusted to, all recent coding changes.